Insider Buying: TearLab Corp Director Purchases 23,000 Shares of Stock (TEAR)
TearLab Corp (NASDAQ:TEAR) Director Brock Wright purchased 23,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was purchased at an average price of $3.82 per share, with a total value of $87,860.00. Following the completion of the purchase, the director now directly owns 657,632 shares in the company, valued at approximately $2,512,154. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
TEAR has been the subject of a number of recent research reports. Analysts at Canaccord Genuity cut their price target on shares of TearLab Corp from $10.00 to $8.00 in a research note on Friday, August 8th. Analysts at Feltl & Co. downgraded shares of TearLab Corp from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 8th.
TearLab Corp (NASDAQ:TEAR) traded down 1.04% on Wednesday, hitting $3.80. 277,531 shares of the company’s stock traded hands. TearLab Corp has a 52 week low of $3.30 and a 52 week high of $13.55. The stock’s 50-day moving average is $4. and its 200-day moving average is $5.46. The company’s market cap is $127.6 million.
TearLab Corp (NASDAQ:TEAR) last released its earnings data on Thursday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. The company had revenue of $9.20 million for the quarter, compared to the consensus estimate of $5.12 million. The company’s revenue for the quarter was up 53.3% on a year-over-year basis. Analysts expect that TearLab Corp will post $-0.67 EPS for the current fiscal year.
TearLab Corp. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.